Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday.

Invivyd Trading Up 13.4%

IVVD stock opened at $0.80 on Thursday. The firm has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $0.76. The company has a market capitalization of $95.84 million, a P/E ratio of -0.67 and a beta of 0.63. Invivyd has a twelve month low of $0.35 and a twelve month high of $2.74.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $34.45 million. Invivyd had a negative return on equity of 165.24% and a negative net margin of 389.01%. On average, research analysts predict that Invivyd will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Jane Street Group LLC grew its position in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after buying an additional 87,358 shares during the last quarter. Barclays PLC boosted its stake in Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after acquiring an additional 9,207 shares during the period. Nuveen LLC bought a new position in shares of Invivyd during the first quarter valued at approximately $65,000. Invesco Ltd. grew its holdings in shares of Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Invivyd during the 1st quarter worth approximately $66,000. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.